September 6, 2017 Thirteen new cases have been filed in Pennsylvania federal court as part of a multidistrict litigation accusing numerous pharmaceutical companies of conspiring to fix the prices of generic drugs.
June 6, 2017 Seven more lawsuits have been filed this week as part of a multidistrict litigation that accuses the pharmaceutical companies of conspiring to fix generic drug prices.
June 1, 2017 Six more lawsuits have been added to a multidistrict litigation that claims various pharmaceutical companies have conspired to fix the price of generic drugs.
May 9, 2017 Four new complaints have been filed in PA federal court as part of a multidistrict litigation that claims various pharmaceutical companies conspired to fix drug prices.
April 25, 2017 Two Louisiana insurance companies have jointly filed two different lawsuits against pharmaceutical companies for allegedly conspiring to fix the prices of generic drugs.
April 6, 2017 Another antitrust lawsuit has been filed against Mylan, its subsidiary, Sandoz, and Taro Pharmaceuticals USA Inc. claiming they conspired to fix generic drug prices.
March 23, 2017 A lawsuit has been filed against nine pharmaceutical companies and their subsidiaries claiming the companies conspired to fix prices of generic pravastatin sodium.
January 3, 2017 The Detectives Endowment Association of the City of New York has filed a proposed class action in Pennsylvania against a collection of drug manufacturers.
December 12, 2016 A proposed class action alleges a who's who of major pharmaceutical companies engaged in a conspiracy to fix the prices of certain generic drugs.
December 6, 2016 The price of pravastatin tablets was artificially inflated as the result of an alleged price-fixing conspiracy between a group of major drug companies.
November 17, 2016 Generic drug makers continue to be the subject of class action litigation alleging they illegally colluded to fraudulently inflate prices of essential drugs.
November 16, 2016 An antirust class action has been filed against a host of generic drug manufacturers claiming the companies illegally conspired to artificially inflate drug prices.
November 9, 2016 A new class action out of California against Mylan Pharmaceuticals and Mylan Specialty L.P. claims the companies illegally inflated the cost of its flagship EpiPen.
October 18, 2016 California and Massachusetts consumers have filed a proposed class action against Mylan claiming the company illegally raised the EpiPen's price by more than 500 percent.
